Symbols / XLO
XLO Chart
About
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 38.73M |
| Enterprise Value | -67.83M | Income | -58.49M | Sales | 31.80M |
| Book/sh | -0.16 | Cash/sh | 1.98 | Dividend Yield | — |
| Payout | 0.00% | Employees | 64 | IPO | — |
| P/E | — | Forward P/E | -0.91 | PEG | — |
| P/S | 1.22 | P/B | -3.38 | P/C | — |
| EV/EBITDA | 1.61 | EV/Sales | -2.13 | Quick Ratio | 2.15 |
| Current Ratio | 2.20 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.61 | EPS next Y | -0.58 | EPS Growth | — |
| Revenue Growth | 7.42% | Earnings | 2025-11-13 07:00 | ROA | -26.26% |
| ROE | -9.08% | ROIC | — | Gross Margin | 82.58% |
| Oper. Margin | -10.12% | Profit Margin | -183.90% | Shs Outstand | 73.46M |
| Shs Float | 15.94M | Short Float | 4.20% | Short Ratio | 4.99 |
| Short Interest | — | 52W High | 1.18 | 52W Low | 0.50 |
| Beta | -0.04 | Avg Volume | 466.05K | Volume | 38.47K |
| Target Price | — | Recom | None | Prev Close | $0.55 |
| Price | $0.53 | Change | -3.46% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.53
Latest analyst target
3. DCF / Fair value
$-5.09
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.53
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-08-06 | init | Leerink Partners | — → Outperform | $2 |
| 2024-11-08 | main | Raymond James | Outperform → Outperform | $4 |
| 2023-05-30 | reit | Chardan Capital | Buy → Buy | $7 |
| 2023-05-11 | reit | Chardan Capital | — → Buy | $7 |
| 2023-01-27 | main | Morgan Stanley | — → Overweight | $10 |
| 2022-12-21 | init | Chardan Capital | — → Buy | $7 |
| 2022-11-10 | main | Raymond James | — → Outperform | $13 |
| 2022-08-10 | main | Morgan Stanley | — → Overweight | $20 |
| 2022-01-10 | init | HC Wainwright & Co. | — → Buy | $36 |
| 2021-11-16 | init | Raymond James | — → Outperform | $31 |
| 2021-11-16 | init | Cowen & Co. | — → Outperform | — |
| 2021-11-16 | init | Morgan Stanley | — → Overweight | $32 |
News
RSS: Latest XLO news- Xilio Therapeutics Shareholders Approve Flexible Reverse Stock Split - TipRanks ue, 24 Feb 2026 13
- Xilio Therapeutics Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis Fri, 26 Dec 2025 08
- Gilead discloses 19.9% stake in Xilio Therapeutics (XLO) ownership filing - Stock Titan hu, 12 Feb 2026 21
- Xilio Therapeutics Announces Pricing of $40 Million Underwritten Offering of Pre-Funded Warrants - Quiver Quantitative hu, 12 Feb 2026 08
- Xilio Therapeutics Announces Pricing of Underwritten Offering - GlobeNewswire hu, 12 Feb 2026 02
- Xilio Stock Jumps 8% On Cancer Drug Data; Gilead Boost Extends Cash Runway Into 2027 — Retail Says Stock Undervalued - Stocktwits Wed, 10 Sep 2025 03
- Xilio Therapeutics (NASDAQ: XLO) raises ~$40M via 74.8M pre-funded warrants - Stock Titan hu, 12 Feb 2026 21
- Xilio Therapeutics prices $40M stock offering - MSN hu, 12 Feb 2026 12
- Xilio Therapeutics Announces $50 Million Public Offering and Potential $150 Million in Total Gross Proceeds - Nasdaq hu, 05 Jun 2025 07
- Xilio Therapeutics Announces Pricing of Underwritten Offering - ChartMill Wed, 11 Feb 2026 08
- Xilio Therapeutics Prices Pre-Funded Warrant Offering Financing - TipRanks hu, 12 Feb 2026 08
- Biotech Xilio brings in $35.8M to advance masked cancer therapies - Stock Titan hu, 08 Jan 2026 08
- Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates - GlobeNewswire hu, 08 Jan 2026 08
- Xilio Therapeutics Reports Promising Phase 2 Data for Vilastobart and Efarindodekin Alfa at SITC 2025 While Announcing Pipeline Advancements and Financial Results - Quiver Quantitative hu, 13 Nov 2025 08
- Xilio Therapeutics Announces Leadership Transition and Pipeline Updates - TipRanks hu, 08 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1826 | 1174.0 | — | Sale at price 0.64 per share. | BRENNAN KEVIN M | Officer | — | 2026-01-02 00:00:00 | D |
| 1 | 7030 | 4522.0 | — | Sale at price 0.64 per share. | FRANKENFIELD CHRISTOPHER JAMES | Chief Financial Officer | — | 2026-01-02 00:00:00 | D |
| 2 | 44250 | nan | — | — | RUSSO RENE PHARM.D. | Chief Executive Officer | — | 2025-12-31 00:00:00 | D |
| 3 | 5000 | nan | — | — | BRENNAN KEVIN M | Officer | — | 2025-12-31 00:00:00 | D |
| 4 | 19375 | nan | — | — | FRANKENFIELD CHRISTOPHER JAMES | Chief Financial Officer | — | 2025-12-31 00:00:00 | D |
| 5 | 16625 | nan | — | — | LUPTAKOVA KATARINA M.D. | Officer | — | 2025-12-31 00:00:00 | D |
| 6 | 13335000 | 9999916.0 | — | Conversion of Exercise of derivative security at price 0.75 per share. | GILEAD SCIENCES INC | Beneficial Owner of more than 10% of a Class of Security | — | 2025-11-26 00:00:00 | D |
| 7 | 70000 | 48085.0 | — | Purchase at price 0.69 per share. | SHANNON JAMES SAMUEL | Director | — | 2025-06-17 00:00:00 | D |
| 8 | 36289 | 24680.0 | — | Purchase at price 0.68 per share. | RUSSO RENE PHARM.D. | Chief Executive Officer | — | 2025-06-16 00:00:00 | D |
| 9 | 1803 | 1774.0 | — | Sale at price 0.98 per share. | BRENNAN KEVIN M | Officer | — | 2025-01-02 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -57.06M | -77.23M | -87.30M | -73.55M |
| TotalUnusualItems | -937.00K | 0.00 | ||
| TotalUnusualItemsExcludingGoodwill | -937.00K | 0.00 | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -58.24M | -76.40M | -88.22M | -75.80M |
| ReconciledDepreciation | 1.64M | 1.90M | 1.85M | 1.50M |
| EBITDA | -58.00M | -77.23M | -87.30M | -73.55M |
| EBIT | -59.65M | -79.13M | -89.15M | -75.04M |
| NormalizedIncome | -57.30M | -76.40M | -88.22M | -75.80M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -58.24M | -76.40M | -88.22M | -75.80M |
| TotalExpenses | 65.99M | 79.13M | 89.15M | 75.04M |
| TotalOperatingIncomeAsReported | -60.58M | -79.13M | -89.15M | -75.04M |
| DilutedAverageShares | 53.51M | 27.50M | 27.39M | 5.61M |
| BasicAverageShares | 53.51M | 27.50M | 27.39M | 5.61M |
| DilutedEPS | -1.09 | -2.78 | -3.22 | -13.52 |
| BasicEPS | -1.09 | -2.78 | -3.22 | -13.52 |
| DilutedNIAvailtoComStockholders | -58.24M | -76.40M | -88.22M | -75.80M |
| NetIncomeCommonStockholders | -58.24M | -76.40M | -88.22M | -75.80M |
| NetIncome | -58.24M | -76.40M | -88.22M | -75.80M |
| NetIncomeIncludingNoncontrollingInterests | -58.24M | -76.40M | -88.22M | -75.80M |
| NetIncomeContinuousOperations | -58.24M | -76.40M | -88.22M | -75.80M |
| PretaxIncome | -58.24M | -76.40M | -88.22M | -75.80M |
| OtherIncomeExpense | 1.40M | 2.73M | 927.00K | -756.00K |
| OtherNonOperatingIncomeExpenses | 2.34M | 2.73M | 927.00K | -756.00K |
| SpecialIncomeCharges | -937.00K | 0.00 | ||
| RestructuringAndMergernAcquisition | 937.00K | 0.00 | ||
| OperatingIncome | -59.65M | -79.13M | -89.15M | -75.04M |
| OperatingExpense | 65.99M | 79.13M | 89.15M | 75.04M |
| ResearchAndDevelopment | 41.21M | 52.14M | 59.20M | 51.19M |
| SellingGeneralAndAdministration | 24.78M | 27.00M | 29.95M | 23.86M |
| GeneralAndAdministrativeExpense | 24.78M | 27.00M | 29.95M | 23.86M |
| OtherGandA | 10.13M | 11.17M | 13.25M | 11.15M |
| SalariesAndWages | 14.65M | 15.83M | 16.70M | 12.71M |
| TotalRevenue | 6.34M | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 6.34M | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 45.76M | 27.61M | 27.43M | 27.36M |
| ShareIssued | 45.76M | 27.61M | 27.43M | 27.36M |
| TotalDebt | 8.14M | 12.50M | 19.94M | 20.54M |
| TangibleBookValue | 17.60M | 36.83M | 105.65M | 185.43M |
| InvestedCapital | 17.60M | 40.14M | 115.48M | 195.06M |
| WorkingCapital | 32.97M | 32.17M | 103.38M | 189.74M |
| NetTangibleAssets | 17.60M | 36.83M | 105.65M | 185.43M |
| CapitalLeaseObligations | 8.14M | 9.19M | 10.11M | 10.91M |
| CommonStockEquity | 17.60M | 36.83M | 105.65M | 185.43M |
| TotalCapitalization | 17.60M | 36.83M | 108.81M | 195.06M |
| TotalEquityGrossMinorityInterest | 17.60M | 36.83M | 105.65M | 185.43M |
| StockholdersEquity | 17.60M | 36.83M | 105.65M | 185.43M |
| RetainedEarnings | -383.75M | -325.51M | -249.11M | -160.89M |
| AdditionalPaidInCapital | 401.35M | 362.34M | 354.75M | 346.31M |
| CapitalStock | 5.00K | 3.00K | 3.00K | 3.00K |
| CommonStock | 5.00K | 3.00K | 3.00K | 3.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 53.48M | 24.10M | 33.52M | 32.63M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 26.22M | 8.14M | 12.40M | 19.85M |
| OtherNonCurrentLiabilities | 45.00K | 118.00K | ||
| NonCurrentDeferredLiabilities | 19.26M | 0.00 | ||
| NonCurrentDeferredRevenue | 19.26M | 0.00 | ||
| LongTermDebtAndCapitalLeaseObligation | 6.95M | 8.14M | 12.35M | 19.73M |
| LongTermCapitalLeaseObligation | 6.95M | 8.14M | 9.19M | 10.11M |
| LongTermDebt | 3.17M | 9.63M | ||
| CurrentLiabilities | 27.26M | 15.96M | 21.12M | 12.78M |
| OtherCurrentLiabilities | 48.00K | 82.00K | 82.00K | |
| CurrentDeferredLiabilities | 13.52M | 0.00 | ||
| CurrentDeferredRevenue | 13.52M | 0.00 | ||
| CurrentDebtAndCapitalLeaseObligation | 1.19M | 4.36M | 7.58M | 801.00K |
| CurrentCapitalLeaseObligation | 1.19M | 1.05M | 918.00K | 801.00K |
| CurrentDebt | 3.31M | 6.67M | ||
| OtherCurrentBorrowings | 3.31M | 6.67M | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 4.21M | 4.69M | 5.41M | 5.14M |
| PayablesAndAccruedExpenses | 8.35M | 6.86M | 8.04M | 6.75M |
| CurrentAccruedExpenses | 5.77M | 5.81M | 4.91M | 3.61M |
| Payables | 2.57M | 1.05M | 3.12M | 3.14M |
| AccountsPayable | 2.57M | 1.05M | 3.12M | 3.14M |
| TotalAssets | 71.08M | 60.93M | 139.16M | 218.06M |
| TotalNonCurrentAssets | 10.84M | 12.80M | 14.67M | 15.54M |
| OtherNonCurrentAssets | 1.78M | 1.73M | 1.83M | 1.95M |
| NetPPE | 9.06M | 11.07M | 12.84M | 13.60M |
| AccumulatedDepreciation | -7.43M | -5.86M | -4.42M | -2.71M |
| GrossPPE | 16.49M | 16.93M | 17.26M | 16.31M |
| Leases | 5.12M | 5.12M | 5.12M | 5.12M |
| ConstructionInProgress | 0.00 | 98.00K | 539.00K | |
| OtherProperties | 10.50M | 10.94M | 11.17M | 9.78M |
| MachineryFurnitureEquipment | 864.00K | 864.00K | 864.00K | 864.00K |
| BuildingsAndImprovements | 4.59M | 5.12M | ||
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 60.23M | 48.13M | 124.50M | 202.52M |
| OtherCurrentAssets | 4.94M | 3.42M | 4.11M | 4.46M |
| PrepaidAssets | 4.11M | 4.46M | ||
| CashCashEquivalentsAndShortTermInvestments | 55.29M | 44.70M | 120.39M | 198.05M |
| CashAndCashEquivalents | 55.29M | 44.70M | 120.39M | 198.05M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -18.41M | -69.11M | -77.59M | -81.85M |
| RepaymentOfDebt | -3.38M | -6.75M | -85.00K | -1.08M |
| IssuanceOfDebt | 0.00 | 975.00K | ||
| IssuanceOfCapitalStock | 6.83M | 0.00 | 0.00 | 261.25M |
| CapitalExpenditure | -36.00K | -486.00K | -1.87M | -1.10M |
| InterestPaidSupplementalData | 62.00K | 573.00K | 555.00K | 492.00K |
| EndCashPosition | 57.07M | 46.29M | 121.95M | 199.61M |
| BeginningCashPosition | 46.29M | 121.95M | 199.61M | 20.79M |
| ChangesInCash | 10.78M | -75.66M | -77.66M | 178.82M |
| FinancingCashFlow | 29.20M | -6.55M | -69.00K | 260.67M |
| CashFlowFromContinuingFinancingActivities | 29.20M | -6.55M | -69.00K | 260.67M |
| NetOtherFinancingCharges | -750.00K | |||
| ProceedsFromStockOptionExercised | 25.75M | 202.00K | 16.00K | 283.00K |
| NetPreferredStockIssuance | 0.00 | 144.89M | ||
| PreferredStockIssuance | 0.00 | 144.89M | ||
| NetCommonStockIssuance | 6.83M | 0.00 | 0.00 | 116.36M |
| CommonStockIssuance | 6.83M | 0.00 | 0.00 | 116.36M |
| NetIssuancePaymentsOfDebt | -3.38M | -6.75M | -85.00K | -110.00K |
| NetLongTermDebtIssuance | -3.38M | -6.75M | -85.00K | -110.00K |
| LongTermDebtPayments | -3.38M | -6.75M | -85.00K | -1.08M |
| LongTermDebtIssuance | 0.00 | 975.00K | ||
| InvestingCashFlow | -36.00K | -486.00K | -1.87M | -1.10M |
| CashFlowFromContinuingInvestingActivities | -36.00K | -486.00K | -1.87M | -1.10M |
| NetPPEPurchaseAndSale | -36.00K | -486.00K | -1.87M | -1.10M |
| PurchaseOfPPE | -36.00K | -486.00K | -1.87M | -1.10M |
| OperatingCashFlow | -18.38M | -68.62M | -75.72M | -80.75M |
| CashFlowFromContinuingOperatingActivities | -18.38M | -68.62M | -75.72M | -80.75M |
| ChangeInWorkingCapital | 31.78M | -1.66M | 2.00M | -11.80M |
| ChangeInOtherWorkingCapital | 32.78M | |||
| ChangeInOtherCurrentLiabilities | -1.05M | -918.00K | -801.00K | -564.00K |
| ChangeInOtherCurrentAssets | 539.00K | 460.00K | 391.00K | 332.00K |
| ChangeInPayablesAndAccruedExpense | 1.03M | -1.89M | 2.07M | -8.44M |
| ChangeInAccruedExpense | -496.00K | 175.00K | 1.58M | -5.62M |
| ChangeInPayable | 1.53M | -2.06M | 485.00K | -2.82M |
| ChangeInAccountPayable | 1.53M | -2.06M | 485.00K | -2.82M |
| ChangeInPrepaidAssets | -1.52M | 688.00K | 344.00K | -3.14M |
| OtherNonCashItems | 157.00K | 223.00K | 173.00K | |
| StockBasedCompensation | 6.43M | 7.38M | 8.42M | 4.96M |
| DepreciationAmortizationDepletion | 1.64M | 1.90M | 1.85M | 1.50M |
| DepreciationAndAmortization | 1.64M | 1.90M | 1.85M | 1.50M |
| OperatingGainsLosses | 3.00K | 3.00K | 1.00K | 222.00K |
| GainLossOnInvestmentSecurities | 203.00K | |||
| GainLossOnSaleOfPPE | 3.00K | 3.00K | 1.00K | 19.00K |
| NetIncomeFromContinuingOperations | -58.24M | -76.40M | -88.22M | -75.80M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for XLO
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|